These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 35045748)

  • 1. Enhancing Radioiodine Incorporation in
    Tchekmedyian V; Dunn L; Sherman E; Baxi SS; Grewal RK; Larson SM; Pentlow KS; Haque S; Tuttle RM; Sabra MM; Fish S; Boucai L; Walters J; Ghossein RA; Seshan VE; Knauf JA; Pfister DG; Fagin JA; Ho AL
    Thyroid; 2022 Mar; 32(3):273-282. PubMed ID: 35045748
    [No Abstract]   [Full Text] [Related]  

  • 2. Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers.
    Dunn LA; Sherman EJ; Baxi SS; Tchekmedyian V; Grewal RK; Larson SM; Pentlow KS; Haque S; Tuttle RM; Sabra MM; Fish S; Boucai L; Walters J; Ghossein RA; Seshan VE; Ni A; Li D; Knauf JA; Pfister DG; Fagin JA; Ho AL
    J Clin Endocrinol Metab; 2019 May; 104(5):1417-1428. PubMed ID: 30256977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol.
    Iravani A; Solomon B; Pattison DA; Jackson P; Ravi Kumar A; Kong G; Hofman MS; Akhurst T; Hicks RJ
    Thyroid; 2019 Nov; 29(11):1634-1645. PubMed ID: 31637953
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical Outcomes of Radioactive Iodine Redifferentiation Therapy in Previously Iodine Refractory Differentiated Thyroid Cancers.
    Toro-Tobon D; Morris JC; Hilger C; Peskey C; Durski JM; Ryder M
    Thyroid; 2024 Jan; 34(1):70-81. PubMed ID: 37917101
    [No Abstract]   [Full Text] [Related]  

  • 5. Redifferentiation of BRAF V600E-Mutated Radioiodine Refractory Metastatic Papillary Thyroid Cancer After Treatment With Dabrafenib and Trametinib.
    Jafri S; Yaqub A
    Cureus; 2021 Aug; 13(8):e17488. PubMed ID: 34595070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation.
    Chakravarty D; Santos E; Ryder M; Knauf JA; Liao XH; West BL; Bollag G; Kolesnick R; Thin TH; Rosen N; Zanzonico P; Larson SM; Refetoff S; Ghossein R; Fagin JA
    J Clin Invest; 2011 Dec; 121(12):4700-11. PubMed ID: 22105174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Robust Thyroid Gene Expression and Radioiodine Uptake Induced by Simultaneous Suppression of BRAF V600E and Histone Deacetylase in Thyroid Cancer Cells.
    Cheng W; Liu R; Zhu G; Wang H; Xing M
    J Clin Endocrinol Metab; 2016 Mar; 101(3):962-71. PubMed ID: 26751190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.
    Brose MS; Cabanillas ME; Cohen EE; Wirth LJ; Riehl T; Yue H; Sherman SI; Sherman EJ
    Lancet Oncol; 2016 Sep; 17(9):1272-82. PubMed ID: 27460442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study.
    Weber M; Kersting D; Riemann B; Brandenburg T; Führer-Sakel D; Grünwald F; Kreissl MC; Dralle H; Weber F; Schmid KW; Herrmann K; Jentzen W; Grafe H; Rischpler C; Theurer S; Bockisch A; Nagarajah J; Fendler WP
    Clin Cancer Res; 2022 Oct; 28(19):4194-4202. PubMed ID: 35594174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations.
    Ofir Dovrat T; Sokol E; Frampton G; Shachar E; Pelles S; Geva R; Wolf I
    Cancer Biol Ther; 2018; 19(10):871-874. PubMed ID: 30036146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The genetic duet of BRAF V600E and TERT promoter mutations predicts the poor curative effect of radioiodine therapy in papillary thyroid cancer.
    Cao J; Zhu X; Sun Y; Li X; Yun C; Zhang W
    Eur J Nucl Med Mol Imaging; 2022 Aug; 49(10):3470-3481. PubMed ID: 35501518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between clinicopathologic factors and FDG avidity in radioiodine-negative recurrent or metastatic differentiated thyroid carcinoma.
    Ha LN; Iravani A; Nhung NT; Hanh NTM; Hutomo F; Son MH
    Cancer Imaging; 2021 Jan; 21(1):8. PubMed ID: 33413689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib.
    Rothenberg SM; McFadden DG; Palmer EL; Daniels GH; Wirth LJ
    Clin Cancer Res; 2015 Mar; 21(5):1028-35. PubMed ID: 25549723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Genetic Duet of
    Liu J; Liu R; Shen X; Zhu G; Li B; Xing M
    J Nucl Med; 2020 Feb; 61(2):177-182. PubMed ID: 31375570
    [No Abstract]   [Full Text] [Related]  

  • 15. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.
    Ho AL; Grewal RK; Leboeuf R; Sherman EJ; Pfister DG; Deandreis D; Pentlow KS; Zanzonico PB; Haque S; Gavane S; Ghossein RA; Ricarte-Filho JC; Domínguez JM; Shen R; Tuttle RM; Larson SM; Fagin JA
    N Engl J Med; 2013 Feb; 368(7):623-32. PubMed ID: 23406027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noninferior response in BRAF(V600E) mutant nonmetastatic papillary thyroid carcinoma to radioiodine therapy.
    Li J; Liang J; Zhao T; Lin Y
    Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1034-9. PubMed ID: 26780618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Add-on radioiodine during long-term BRAF/MEK inhibition in patients with RAI-refractory thyroid cancers: a reasonable option?
    Montes de Jesus FM; Espeli V; Paone G; Giovanella L
    Endocrine; 2023 Sep; 81(3):450-454. PubMed ID: 37191938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
    Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC
    Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterizing Genetic Alterations Related to Radioiodine Avidity in Metastatic Thyroid Cancer.
    Mu Z; Zhang X; Sun D; Sun Y; Shi C; Ju G; Kai Z; Huang L; Chen L; Liang J; Lin Y
    J Clin Endocrinol Metab; 2024 Apr; 109(5):1231-1240. PubMed ID: 38060243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation.
    Kim KB; Cabanillas ME; Lazar AJ; Williams MD; Sanders DL; Ilagan JL; Nolop K; Lee RJ; Sherman SI
    Thyroid; 2013 Oct; 23(10):1277-83. PubMed ID: 23489023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.